International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome

Osilodrostat controls hypercortisolism in 66.7% of patients with adrenal CS treated for longer than 4 weeks and in 87.5% of cases treated for longer than 12 weeks, with a positive impact on blood pressure and body weight. Patients who received osilodrostat after other previous steroidogenesis inhibitors have a higher probability of response.

Authors

Institutions

Publication Details

Journal
The Journal of Clinical Endocrinology & Metabolism
Published
2026-03-12
DOI
https://doi.org/10.1210/clinem/dgag115
Citations
1
Primary Topic
Pituitary Gland Disorders and Treatments
Type
article
Field-Weighted Citation Impact
30.73
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome

Ana Castro Luna, Markus Kroiss, Ana Echarri, Barbara Altieri et al.
1 citations
The Journal of Clinical Endocrinology & Metabolism
Pituitary Gland Disorders and Treatments
30.73
article

International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome

Ana Castro Luna, Markus Kroiss, Ana Echarri, Barbara Altieri, Paola Gracia Gimeno, Matthias Oettle, William Martínez, Rogelio García-Centeno, Haibo Lu, María Dolores Ollero García-Agulló, Fernando Guerrero-Pérez, I. Bancos, Mario Detomas, Salehi Mahdi, Felicia A Hanzu, Marta Araujo-Castro, María Pasarón, Martin Reincke, Lucía Manzano Valero, Laura Gónzalez-Fernandez
article en
1 citations

Abstract

Osilodrostat controls hypercortisolism in 66.7% of patients with adrenal CS treated for longer than 4 weeks and in 87.5% of cases treated for longer than 12 weeks, with a positive impact on blood pressure and body weight. Patients who received osilodrostat after other previous steroidogenesis inhibitors have a higher probability of response.

The Journal of Clinical Endocrinology & Metabolism
Mayo Clinic (US), Henan University of Science and Technology (CN), Instituto Cajal (ES), Bellvitge University Hospital (ES), ProMedica Toledo Hospital (US), Hospital General Universitario Gregorio Marañón (ES), LMU Klinikum (DE), Institut d'Investigació Biomédica de Bellvitge (ES), Complejo Hospitalario de Navarra (ES), Hospital Royo Villanova (ES), Hospital Clínic de Barcelona (ES), Mayo Clinic in Arizona (US), Universitätsklinikum Würzburg (DE), Instituto Ramón y Cajal de Investigación Sanitaria (ES), First Affiliated Hospital of Henan University of Science and Technology (CN), Mayo Clinic in Florida (US), Hospital Universitario De Cabueñes (ES), Hospital de Clínicas (UY), Hospital Universitario Ramón y Cajal (ES), Universitat de Barcelona (ES), Ludwig-Maximilians-Universität München (DE), Universidad de Navarra (ES)
Good health and well-being
Openalex Percentile: Top 0%
Pituitary Gland Disorders and Treatments
30.73
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.